SOST (resugobart Biosimilar) Recombinant Monoclonal Antibody

說明書

貨號：

CSB-RA858415MB1HU
規(guī)格：
其他：

產(chǎn)品詳情
產(chǎn)品評價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

Q9BQB4
基因名：

SOST
別名：

BEER antibody; CDD antibody; Cortical hyperostosis with syndactyly antibody; Sclerosteosis antibody; Sclerostin antibody; Sost antibody; SOST_HUMAN antibody; SOST1 antibody; UNQ2976/PRO7455/PRO7476 antibody; VBCH antibody
反應(yīng)種屬：

Human
免疫原：

Recombinant Human SOST protein
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.115
產(chǎn)品提供形式：

Liquid
應(yīng)用說明：

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

In stock
用途：

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

功能：

Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
基因功能參考文獻(xiàn)：
1. Sclerostin is degraded by cathepsin K in vitro. Cathepsin K degradation of sclerostin is affected by hypoxia. PMID: 29859187
2. Study found that sclerostin concentrations were not significantly higher in patients with bone metastases compared to non-metastatic prostate cancer (PC) but they were significantly higher in patients with CRPC. Sclerostin levels were significantly higher in patients with advanced disease and increased bone turnover due to a compensatory response to the increased number of osteoblasts. PMID: 30116403
3. Patients with Latent autoimmune diabetes in Adults (LADA) presented lower bone resorption than did controls, similar to patients with T2 diabetes (T2D). Sclerostin is increased in T2D but not in LADA, suggesting possible roles on bone metabolism in T2D only. PMID: 29506222
4. Higher Sclerostin/SOST expression is associated with lower percentage of circulatory blasts and better prognosis in patients with myelofibrosis. PMID: 29532161
5. Sclerosteosis is caused by loss-of-function mutations in the SOST gene which encodes a secreted glycoprotein, sclerostin--{REVIEW} PMID: 29080811
6. Serum sclerostin level was not an independent predictor of mortality in Maintenance Hemodialysis Patients PMID: 29940587
7. these results suggest a possible role of sclerostin in the identification of ankylosing spondylitis patients PMID: 29854850
8. important role for SOST SNP rs1877632 and VDR SNPs rs10735810 and rs731236 in the pathophysiology of stress fracture PMID: 29129460
9. Sclerostin increased after exercise in comparison to baseline (mean +/- SEM: 410 +/- 27 vs. 290 +/- 19 pg/mL; p < 0.001) corresponding to an increase of +44.3 +/-5.5% PMID: 28374174
10. serum sclerostin levels correlated positively with carotid intima-media thickness and inversely with the augmentation index, a marker of arterial stiffness PMID: 28339088
11. The difference of serum sclerostin levels in Ankylosing Spondylitis and Rheumatoid Arthritis patients was not significantly different from HC, indicating that the sclerostin may not associate with the development of Ankylosing Spondylitis and Rheumatoid Arthritis. PMID: 28553652
12. SOST gene silencing promotes the proliferation, invasion, and migration, and inhibits apoptosis of osteosarcoma cells by activating Wnt/beta-catenin signaling pathway PMID: 28246931
13. No difference was found in the serum sclerostin levels between the hyperthyroidism patients and healthy control. PMID: 29059259
14. Positivity of RANKL and anti-CCP2 yielded significant risk for progression with negativity for both as reference. No single nucleotide polymorphism encoding TNFSF11 or SOST was associated with increased concentrations of the factors. PMID: 28190118
15. Osterix and RUNX2 are transcriptional regulators of sclerostin in human bone PMID: 27154028
16. An association was found between rs851054 of the SOST promoter and the fracture rate during childhood osteogenesis imperfecta. PMID: 27519970
17. The increased expression of sclerostin in the liver and the association with histologic cholangitis may explain the high serum levels of this protein in patients with primary biliary cirrhosis. PMID: 27019303
18. SOST silencing promotes the proliferation, invasion and migration, and decreases the apoptosis of human retinoblastoma cells by activating the Wnt/beta-catenin signaling pathway. PMID: 28485721
19. Sclerostin concentrations in serum significantly decreased and IGF-I significantly increased after 12months of resistance training or JUMP. PMID: 27744012
20. observed an association between sclerostin levels with fasting insulin levels and homoeostatic model assessment-insulin resistance, but there was no clear association with type 2 diabetes risk. PMID: 28090669
21. Sclerostin levels in KTR are normal and influenced more by bone turnover than by eGFR. Its involvement with other hormones of mineral homeostasis (FGF23/Klotho and Vitamin D) is part of the sophisticated cross-talk between bone and the kidney PMID: 28558021
22. Vitamin D receptor agonism by paricalcitol causes a moderate increase in serum sclerostin in CKD patients, and this effect is modified by circulating pentosidine levels. PMID: 28017524
23. SOST is frequently expressed in skeletal bone- and cartilage-forming tumors. The strong spatial correlation with bone formation and the in vitro expression patterns are in line with the known functions of SOST in nonneoplastic bone, as a feedback inhibitor on osteogenic differentiation. PMID: 27498059
24. Intermittent compressive stress regulates Notch receptor and target gene expression via the TGF-beta signaling pathway. Notch signaling participates in TGF-beta-induced sclerostin expression in periodontal ligament cells. PMID: 27966788
25. Dickkopf-1 and sclerostin were never correlated with each other or with bone turnover markers patients with Paget's disease of bone. Sclerostin was positively correlated with age. PMID: 28054306
26. These data suggest that sclerostin plays an important role in the bone remodeling of tooth movement. PMID: 28081119
27. SOST is expressed in the aorta and downregulated in human aortic aneurysms and atherosclerosis, possibly because of epigenetic silencing. PMID: 28062506
28. The level of sclerostin was higher in the female obstructive sleep apnea (OSA) patients than that in female controls. Further, in OSA women with cardiovascular comorbidities, sclerostin was higher than in women without such comorbidities. In men, there were no differences in the serum sclerostin level between the OSA and control subjects, nor was there any relationship with cardiovascular diseases. PMID: 26820731
29. Knockdown of SOST in MG-63 cells increases osteogenesis and ratio of OPG/RANKL in vitro PMID: 27774939
30. The findings confirm that the human SOST gene and sclerostin expression can be considered to be directly 1,25-dihydroxyvitamin D-responsive in osteocytes. PMID: 26690786
31. Sclerostin is an osteocyte marker that is strongly expressed in human woven and lamellar bone and mineralizing chondrocytes PMID: 26896083
32. similar levels in type 1 diabetes patients and controls; decrease concurrent with adolescent growth spurt PMID: 26094958
33. Findings indicate that sclerostin expression is closely associated with the degree of joint damage in primary knee osteoarthritis (OA), confirming its involvement in the development of OA. PMID: 27665782
34. Results suggest that sclerostin may have a role in the development of or the response to abdominal aortic calcification in chronic kidney disease. PMID: 27165564
35. serum sclerostin levels were lower in nonalcoholic steatohepatitis patients than in controls. PMID: 26056025
36. The aim of this study was to evaluate the renal handling of sclerostin. PMID: 27214309
37. chronic TNFalpha (tumor necrosis factor alpha)-dependent arthritis, fibroblast-like synoviocytes constitute a major source of sclerostin and that either the lack of sclerostin or its antibody-mediated inhibition leads to an acceleration of rheumatoid arthritis (RA)-like disease. PMID: 27089204
38. Sclerostin levels are elevated in CKD patients and are associated with inflammation, vascular lesions, uremia and (potentially) mortality. PMID: 25070604
39. Our data also demonstrated that vitamin D deficient newborns exhibited lower sclerostin levels than vitamin D sufficient newborns. PMID: 26352089
40. the first evidence suggesting that LRP4 is responsible for the retention of sclerostin in the bone environment in humans. PMID: 26751728
41. higher serum sclerostin levels are associated with higher bone mineral density, lower aortic calcification scores, and a better survival rate in hemodialysis patients PMID: 26890570
42. findings suggest that serum TGF-beta1 level increases during postmenopause and declines in old age. Sclerostin production is inhibited by TGF-beta1 during early postmenopause PMID: 26826396
43. a cell model of human dermal fibroblasts in order to investigate the functions of sclerostin, is reported. PMID: 26851122
44. The aims of this study were to evaluate OCN and sclerostin levels in subjects who underwent coronary artery bypass graft (CABG) surgery compared with those in normal controls. PMID: 26576474
45. two affected siblings who carried a novel nonsense mutation of SOST in a consanguineous family from China, is reported. PMID: 26283468
46. Sclerostin serum levels are not associated with an adverse metabolic profile during pregnancy in women with GDM and PE PMID: 25753744
47. Quantitative RT-PCR analysis showed that SOST expression dose-dependently decreased with increasing Wnt signaling, while BMP4 induced SOST expression PMID: 26095393
48. The correlation of SOST polymorphisms with changes of BMD and bone biomarkers after treatment was analyzed. PMID: 26250343
49. highly sulfated glycosaminoglycans might control bone homeostasis via interference with sclerostin/LRP5/6 complex formation. PMID: 26232882
50. Serum sclerostin was associated with serum intact parathyroid hormone in patients undergoing peritoneal dialysis. PMID: 25974190
顯示更多

收起更多
相關(guān)疾病：

Sclerosteosis 1 (SOST1); Van Buchem disease (VBCH); Craniodiaphyseal dysplasia autosomal dominant (CDD)
亞細(xì)胞定位：

Secreted, extracellular space, extracellular matrix.
蛋白家族：

Sclerostin family
組織特異性：

Widely expressed at low levels with highest levels in bone, cartilage, kidney, liver, bone marrow and primary osteoblasts differentiated for 21 days. Detected in the subendothelial layer of the aortic intima (at protein level).
數(shù)據(jù)庫鏈接：

HGNC: 13771

OMIM: 122860

KEGG: hsa:50964

STRING: 9606.ENSP00000301691

UniGene: Hs.349204

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human